CClinicalTrials.gg
Status unknownNCT05646654Updated Apr 19, 2023

Interscalene Block Versus Erector Spinae Plane Block for Shoulder Arthroscopy Anesthesia

An interventional study of Erector spinae plane block and Interscalene brachial plexus block in Interscalene Block, Erector Spinae Plane Block and Arthroscopy, sponsored by Tanta University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Tanta University · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study is to compare the effectiveness of ESPB versus ISB in anesthesia for shoulder arthroscopy

Read the detailed description

Regional anesthetic techniques can control pain effectively, both at rest and on movement, allowing earlier mobilization without the adverse effects of opioids. Among the various types of regional anesthetic techniques, the interscalene brachial plexus block (ISB) is a gold standard used nerve block technique for postoperative analgesia in patients undergoing shoulder surgery, as it has consistently been shown to significantly control.

the interscalene brachial plexus block (ISB) regional anesthesia offers many advantages over general anesthesia for both arthroscopic and open surgeries of the shoulder it provides excellent intraoperative anesthesia and muscle relaxation' as well as analgesia that continues into the postoperative period

02

Conditions studied

  • Interscalene Block
  • Erector Spinae Plane Block
  • Arthroscopy
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients with Body Mass Index \< 40 kg/m2
  • American Society of Anesthesiologists (ASA) physical status I-II
  • scheduled for elective shoulder arthroscopy

Exclusion criteria

Exclusion Criteria:

  • Known allergy to local anesthetics
  • Allergy to all opioid medications
  • Diagnostic shoulder arthroscopic procedures
  • Patients with chronic opioids
  • Patients who converted to general anesthesia use and coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    Erector spinae plane block group

    3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected.

    Procedure: Erector spinae plane block

  • Active comparator
    Interscalene group

    Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots

    Procedure: Interscalene brachial plexus block

Interventions

  • ProcedureErector spinae plane block

    Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected

  • ProcedureInterscalene brachial plexus block

    Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots

06

What researchers measure

Primary outcomes

  1. Intraoperative fentanyl consumption

    Fntanyl will be administered 1 µg/kg IV increments.

    Time frame: 30 minutes

Secondary outcomes

  1. Postoperative pain

    numeric rating scale (NRS) (0 represents "no pain" while 10 represents "the worst pain imaginable").

    Time frame: 24 hours postoperative

  2. Rescue analgesia in the form of IV meperidine (0.5 mg/kg) boluses if NRS >3. Time to the 1st rescue analgesic request will be recorded

    Time frame: 24 hours postoperative

  3. Total amount of rescue analgesic

    Rescue analgesia in the form of IV meperidine (0.5 mg/kg) boluses if NRS \>3.

    Time frame: 24 hours postoperative

07

Study locations

1 of 1 sites recruiting
  • Islam Morsy
    Tanta, El-Gharbia 31527, Egypt
    • Islam Morsy · Contact · eslam.morsy@med.tanta.edu.eg · 00201093387374
    • Hussein G Almawardy, MD · Principal investigator
    • Mohammed S ElSharkawy, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon reasonable request from the principal investigator

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05646654
Lead sponsor
Tanta University
Responsible party
Islam Morsy (Lecturer of Anesthesia, Surgical Intensive Care and Pain Medicine, Tanta University) — Principal investigator
First posted
Dec 12, 2022
Start date
Dec 15, 2022
Primary completion
May 15, 2023 (estimated)
Completion
May 15, 2023 (estimated)
Last update
Apr 19, 2023

Study contacts

Islam Morsy, MD
Contact
eslam.morsy@med.tanta.edu.eg
00201093387374 ext. 139
Islam Morsy
Contact
eslam.morsy@med.tanta.edu.eg
00201093387374 ext. 139

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion